Sunitinib Versus Placebo for Patients with Advanced Unresectable Pancreatic Neuroendocrine Tumors

From ASCO 2011 -- A discussion with Prof. Eric Raymond on his poster presented at ASCO in June 2011 titled "Updated Overall Survival (OS) and Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) of Sunitinib Versus Placebo for Patients with Advanced Unresectable Pancreatic Neuroendocrine Tumors (NET)"

• kategori